Know Cancer

or
forgot password

Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study


Phase 2
18 Years
N/A
Not Enrolling
Both
Lymphoma, Non-Hodgkin

Thank you

Trial Information

Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study


Inclusion Criteria:



- Histologic diagnosis of NHL:Any histology

- Stage I-IV

- Measurable disease by CT scan (gross disease measuring at least 2 cm in any one
dimension)

- Planned radiation dose prescription >=30 gy, >=20 fractions, >=3weeks duration

- Informed consent

- Previous chemotherapy is allowed, provided the above eligibility criteria are me

Exclusion Criteria:

- To minimize effect from breathing motion, patients presenting with parenchymal lung
tumours and tumours involving liver and stomach will be excluded

- Concurrent systemic chemotherapy (glucocorticoids when used alone is allowed)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To quantify spatial and temporal treatment response to radiation therapy in patients with NHL using the co-registered CT and FDG-PET images and assess this response with temporal geometric models.

Principal Investigator

Richard Tsang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Princess Margaret Hospital, Canada

Authority:

Canada: Ethics Review Committee

Study ID:

UHN REB 05-0339-C

NCT ID:

NCT00188929

Start Date:

August 2005

Completion Date:

July 2009

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location